Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Gregory Schwartz to Humans

This is a "connection" page, showing publications Gregory Schwartz has written about Humans.

 
Connection Strength
  
 
 
1.155
  
  1. Landmesser U, Koenig W, Leiter LA, Raal FJ, Ray KK, Wright RS, Han J, Conde LG, Schwartz GG. Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials. Atherosclerosis. 2023 12; 386:117354.
    View in: PubMed
    Score: 0.025
  2. Kovach CP, Mesenbring EC, Gupta P, Glorioso TJ, Ho PM, Waldo SW, Schwartz GG. Projected Outcomes of Optimized Statin and Ezetimibe Therapy in US Military Veterans with Coronary Artery Disease. JAMA Netw Open. 2023 08 01; 6(8):e2329066.
    View in: PubMed
    Score: 0.024
  3. Schwartz GG, Szarek M, Zeiher A, White HD, Jukema JW, Harrington RA, Goodman SG, Diaz R, Bittner V, Bhatt DL, Steg PG. Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of?Alirocumab. J Am Coll Cardiol. 2022 12 13; 80(24):2356-2359.
    View in: PubMed
    Score: 0.023
  4. Schwartz GG, Giugliano RP. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction. Curr Opin Lipidol. 2022 06 01; 33(3):147-159.
    View in: PubMed
    Score: 0.022
  5. Schwartz GG, Ballantyne CM. Existing and emerging strategies to lower Lipoprotein(a). Atherosclerosis. 2022 05; 349:110-122.
    View in: PubMed
    Score: 0.022
  6. White HD, Steg PG, Schwartz GG. Myocardial Infarction and Evolocumab. JAMA Cardiol. 2021 10 01; 6(10):1220-1221.
    View in: PubMed
    Score: 0.021
  7. Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, L?pez-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. J Am Coll Cardiol. 2021 08 03; 78(5):421-433.
    View in: PubMed
    Score: 0.021
  8. Schwartz GG, Nicholls SJ, Toth PP, Sweeney M, Halliday C, Johansson JO, Wong NCW, Kulikowski E, Kalantar-Zadeh K, Ginsberg HN, Ray KK. Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial. Cardiovasc Diabetol. 2021 06 22; 20(1):125.
    View in: PubMed
    Score: 0.021
  9. Schwartz GG, Szarek M, Bittner VA, Bhatt DL, Diaz R, Goodman SG, Jukema JW, Loy M, Manvelian G, Pordy R, White HD, Steg PG. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. Diabetes Care. 2021 05; 44(5):1219-1227.
    View in: PubMed
    Score: 0.021
  10. Schwartz GG, Gabriel Steg P, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Jukema JW, Kim YU, Li QH, Manvelian G, Pordy R, Sourdille T, White HD, Szarek M. Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. Circulation. 2021 03 16; 143(11):1109-1122.
    View in: PubMed
    Score: 0.020
  11. Sabatine MS, Giugliano RP, Schwartz GG. Letter to the editor re: 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'. Expert Rev Clin Pharmacol. 2021 02; 14(2):281-282.
    View in: PubMed
    Score: 0.020
  12. Schwartz GG, Szarek M, Bittner VA, Steg PG. Response by Schwartz et al to Letter Regarding Article, "Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial". Circulation. 2020 11 17; 142(20):e335-e336.
    View in: PubMed
    Score: 0.020
  13. Salahuddin T, Richardson V, McNeal DM, Henderson K, Hess PL, Raghavan S, Saxon DR, Valle JA, Waldo SW, Ho PM, Schwartz GG. Potential unrealized mortality benefit of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transport-2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program. Diabetes Obes Metab. 2021 01; 23(1):97-105.
    View in: PubMed
    Score: 0.020
  14. Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, Kim YU, Jukema JW, Pordy R, Roe MT, White HD, Bhatt DL. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. Circulation. 2020 05 19; 141(20):1608-1617.
    View in: PubMed
    Score: 0.019
  15. Schwartz GG, Leiter LA, Ballantyne CM, Barter PJ, Black DM, Kallend D, Laghrissi-Thode F, Leitersdorf E, McMurray JJV, Nicholls SJ, Olsson AG, Preiss D, Shah PK, Tardif JC, Kittelson J. Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. Diabetes Care. 2020 05; 43(5):1077-1084.
    View in: PubMed
    Score: 0.019
  16. Salahuddin T, Kittelson J, Tardif JC, Shah PK, Olsson AG, Nicholls SJ, Leitersdorf E, Leiter LA, Kallend D, Black DM, Barter PJ, Ballantyne CM, Schwartz GG. Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. Am Heart J. 2020 03; 221:60-66.
    View in: PubMed
    Score: 0.019
  17. Schwartz GG, Chaitman BR. Initiating PCSK9 Inhibition in Hospital for ACS: We Can, But Does That Mean We Should? J Am Coll Cardiol. 2019 11 19; 74(20):2463-2465.
    View in: PubMed
    Score: 0.019
  18. Szarek M, Steg PG, DiCenso D, Bhatt DL, Bittner VA, Budaj A, Diaz R, Goodman SG, Gotcheva N, Jukema JW, Pordy R, Roe MT, Sourdille T, White HD, Xavier D, Zeiher AM, Schwartz GG. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. Circ Cardiovasc Qual Outcomes. 2019 11; 12(11):e005858.
    View in: PubMed
    Score: 0.019
  19. Roe MT, Li QH, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Lopez-Jaramillo P, Lopes RD, Louie MJ, Moriarty PM, Szarek M, Vogel R, White HD, Zeiher AM, Baccara-Dinet MT, Steg PG, Schwartz GG. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation. 2019 11 05; 140(19):1578-1589.
    View in: PubMed
    Score: 0.019
  20. Ray KK, Nicholls SJ, Ginsberg HD, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Cummings JL, Sweeney M, Schwartz GG. Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. Am Heart J. 2019 11; 217:72-83.
    View in: PubMed
    Score: 0.018
  21. Schwartz GG, Taylor MRG. PCSK9 Function and Cardiovascular?Death: The Knot Tightens. J Am Coll Cardiol. 2019 06 25; 73(24):3115-3117.
    View in: PubMed
    Score: 0.018
  22. Schwartz GG, Steg PG, Szarek M. Alirocumab after Acute Coronary Syndrome. Reply. N Engl J Med. 2019 05 23; 380(21):2077.
    View in: PubMed
    Score: 0.018
  23. Steg PG, Szarek M, Bhatt DL, Bittner VA, Br?geault MF, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Ostadal P, Parkhomenko A, Pordy R, Roe MT, Tricoci P, Vogel R, White HD, Zeiher AM, Schwartz GG. Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation. 2019 07 09; 140(2):103-112.
    View in: PubMed
    Score: 0.018
  24. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018 11 29; 379(22):2097-2107.
    View in: PubMed
    Score: 0.018
  25. St?hli BE, Nozza A, Schrieks IC, Buse JB, Malmberg K, Mellbin L, Neal B, Nicholls SJ, Ryd?n L, Svensson A, Wedel H, Weichert A, Lincoff AM, Grobbee DE, Tardif JC, Schwartz GG. Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome. J Clin Endocrinol Metab. 2018 07 01; 103(7):2522-2533.
    View in: PubMed
    Score: 0.017
  26. Schrieks IC, Nozza A, St?hli BE, Buse JB, Henry RR, Malmberg K, Neal B, Nicholls SJ, Ryd?n L, Mellbin L, Svensson A, Wedel H, Weichert A, Lincoff AM, Tardif JC, Grobbee DE, Schwartz GG. Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome. Diabetes Care. 2018 08; 41(8):1792-1800.
    View in: PubMed
    Score: 0.017
  27. Nicholls SJ, Ray KK, Johansson JO, Gordon A, Sweeney M, Halliday C, Kulikowski E, Wong N, Kim SW, Schwartz GG. Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease. Am J Cardiovasc Drugs. 2018 Apr; 18(2):109-115.
    View in: PubMed
    Score: 0.017
  28. Schwartz GG, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Nicholls SJ, Olsson AG, Shah PK, Tardif JC, Kittelson J. Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. JAMA Cardiol. 2018 02 01; 3(2):164-168.
    View in: PubMed
    Score: 0.017
  29. Schwartz GG, Fayyad R, Szarek M, DeMicco D, Olsson AG. Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndrome. Eur J Prev Cardiol. 2017 08; 24(12):1294-1296.
    View in: PubMed
    Score: 0.016
  30. Pitts R, Gunzburger E, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, Nicholls SJ, Shah PK, Tardif JC, Olsson AG, McMurray JJ, Kittelson J, Schwartz GG. Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. J Am Heart Assoc. 2017 01 10; 6(1).
    View in: PubMed
    Score: 0.015
  31. Pitts R, Gunzburger E, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Nicholls SJ, Niesor EJ, Olsson AG, Shah PK, Tardif JC, Kittelson J, Schwartz GG. Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. J Am Coll Cardiol. 2016 12 06; 68(22):2488-2490.
    View in: PubMed
    Score: 0.015
  32. Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, Mundl H, Olsson AG. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015 Jun 02; 65(21):2267-75.
    View in: PubMed
    Score: 0.014
  33. Do RQ, Nicholls SJ, Schwartz GG. Evolving targets for lipid-modifying therapy. EMBO Mol Med. 2014 Oct; 6(10):1215-30.
    View in: PubMed
    Score: 0.013
  34. Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014 Nov; 168(5):682-9.
    View in: PubMed
    Score: 0.013
  35. Do RQ, Vogel RA, Schwartz GG. PCSK9 Inhibitors: potential in cardiovascular therapeutics. Curr Cardiol Rep. 2013 Mar; 15(3):345.
    View in: PubMed
    Score: 0.012
  36. Schwartz GG, Olsson AG, Barter PJ. Dalcetrapib in patients with an acute coronary syndrome. N Engl J Med. 2013 02 28; 368(9):869-70.
    View in: PubMed
    Score: 0.012
  37. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Nov 29; 367(22):2089-99.
    View in: PubMed
    Score: 0.012
  38. Huang JV, Greyson CR, Schwartz GG. PPAR-? as a therapeutic target in cardiovascular disease: evidence and uncertainty. J Lipid Res. 2012 Sep; 53(9):1738-54.
    View in: PubMed
    Score: 0.011
  39. Schwartz GG. New horizons for cholesterol ester transfer protein inhibitors. Curr Atheroscler Rep. 2012 Feb; 14(1):41-8.
    View in: PubMed
    Score: 0.011
  40. Schwartz GG, Chaitman BR, Goldberger JJ, Messig M. High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Am Heart J. 2011 May; 161(5):993-9.
    View in: PubMed
    Score: 0.010
  41. Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J. 2009 Dec; 158(6):896-901.e3.
    View in: PubMed
    Score: 0.009
  42. Schwartz GG. High-density lipoprotein cholesterol as a risk factor and target of therapy after acute coronary syndrome. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):46E-51E.
    View in: PubMed
    Score: 0.009
  43. Schwartz GG. Lipid management after acute coronary syndrome. Curr Opin Lipidol. 2007 Dec; 18(6):626-32.
    View in: PubMed
    Score: 0.008
  44. Schwartz GG, Olsson AG, Szarek M, Sasiela WJ. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care. 2005 Oct; 28(10):2508-13.
    View in: PubMed
    Score: 0.007
  45. Schwartz GG, Olsson AG. The case for intensive statin therapy after acute coronary syndromes. Am J Cardiol. 2005 Sep 05; 96(5A):45F-53F.
    View in: PubMed
    Score: 0.007
  46. Schwartz GG. Statins in acute coronary syndromes: the sooner, the better? Am Heart J. 2005 Mar; 149(3):377-80.
    View in: PubMed
    Score: 0.007
  47. Schwartz GG, Bolognese MA, Tremblay BP, Caplan R, Hutchinson H, Raza A, Cressman M. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Am Heart J. 2004 Jul; 148(1):e4.
    View in: PubMed
    Score: 0.006
  48. Savonitto S, Morici N, Pancani S, Nozza A, Cosentino F, Perrone Filardi P, Cavallini C, Angeli F, St?hli BE, Heerspink HJL, Mannini A, Schwartz GG, Lincoff AM, Tardif JC, Grobbee DE. Impact of age on the predictive value of NT-proBNP in patients with diabetes mellitus stabilised after an acute coronary syndrome. Diabetes Res Clin Pract. 2024 Feb; 208:111112.
    View in: PubMed
    Score: 0.006
  49. Wright RS, Koenig W, Landmesser U, Leiter LA, Raal FJ, Schwartz GG, Lesogor A, Maheux P, Stratz C, Zang X, Ray KK. Safety and Tolerability of Inclisiran for?Treatment of Hypercholesterolemia in?7 Clinical Trials. J Am Coll Cardiol. 2023 12 12; 82(24):2251-2261.
    View in: PubMed
    Score: 0.006
  50. Schwartz GG, Ganz P, Waters D, Arikian S. Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. Am J Cardiol. 2003 Nov 01; 92(9):1109-12.
    View in: PubMed
    Score: 0.006
  51. Goodman SG, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Diaz R, Garon G, Harrington RA, Jukema JW, Manvelian G, Stipek W, Szarek M, White HD, Schwartz GG. Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5?Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial. J Am Heart Assoc. 2023 09 19; 12(18):e029216.
    View in: PubMed
    Score: 0.006
  52. Szarek M, Reijnders E, Jukema JW, Bhatt DL, Bittner VA, Diaz R, Fazio S, Garon G, Goodman SG, Harrington RA, Ruhaak LR, Schwertfeger M, Tsimikas S, White HD, Steg PG, Cobbaert C, Schwartz GG. Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests. Circulation. 2024 01 16; 149(3):192-203.
    View in: PubMed
    Score: 0.006
  53. Mohammadi KA, Brackin T, Schwartz GG, Steg PG, Szarek M, Manvelian G, Pordy R, Fazio S, Geba GP. Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials. Cancer Med. 2023 08; 12(16):16859-16868.
    View in: PubMed
    Score: 0.006
  54. Suc G, Schwartz GG, Goodman SG, Jukema JW, Manvelian G, Poulouin Y, Pordy R, Scemama M, Szarek M, Steg PG. Effect of alirocumab on cataracts in patients with acute coronary syndromes. BMC Ophthalmol. 2023 Jun 16; 23(1):279.
    View in: PubMed
    Score: 0.006
  55. Steg PG, Szarek M, Valgimigli M, Islam S, Zeiher AM, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Goodman SG, Gotcheva N, Harrington RA, Jukema JW, Kim HS, Kim SH, Morais J, Pordy R, Scemama M, White HD, Schwartz GG. Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome. Can J Cardiol. 2023 10; 39(10):1315-1324.
    View in: PubMed
    Score: 0.006
  56. Ray KK, Raal FJ, Kallend DG, Jaros MJ, Koenig W, Leiter LA, Landmesser U, Schwartz GG, Lawrence D, Friedman A, Garcia Conde L, Wright RS. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023 01 07; 44(2):129-138.
    View in: PubMed
    Score: 0.006
  57. Koenig W, Conde LG, Landmesser U, Leiter LA, Ray KK, Schwartz GG, Wright RS, Han J, Raal FJ. Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials. Cardiovasc Drugs Ther. 2024 Jun; 38(3):493-503.
    View in: PubMed
    Score: 0.006
  58. Ray KK, Kallend D, Leiter LA, Raal FJ, Koenig W, Jaros MJ, Schwartz GG, Landmesser U, Garcia Conde L, Wright RS. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022 12 21; 43(48):5047-5057.
    View in: PubMed
    Score: 0.006
  59. Grobbee EJ, de Jong VD, Schrieks IC, Tushuizen ME, Holleboom AG, Tardif JC, Lincoff AM, Schwartz GG, Castro Cabezas M, Grobbee DE. Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-a/? agonist aleglitazar. PLoS One. 2022; 17(11):e0277706.
    View in: PubMed
    Score: 0.006
  60. Landmesser U, McGinniss J, Steg PG, Bhatt DL, Bittner VA, Diaz R, Dilic M, Goodman SG, Jukema JW, Loy M, Pecin I, Pordy R, Poulsen SH, Szarek M, White HD, Schwartz GG. Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. Eur J Prev Cardiol. 2022 10 20; 29(14):1842-1851.
    View in: PubMed
    Score: 0.006
  61. Moriarty PM, Steg PG, McGinniss J, Zeiher AM, White HD, Manvelian G, Pordy R, Loy M, Jukema JW, Harrington RA, Gray JV, Gorby LK, Goodman SG, Diaz R, Bittner VA, Bhatt DL, Szarek M, Schwartz GG. Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes. J Clin Lipidol. 2022 Sep-Oct; 16(5):747-756.
    View in: PubMed
    Score: 0.006
  62. Hagstr?m E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation. 2022 08 30; 146(9):657-672.
    View in: PubMed
    Score: 0.006
  63. Chiang CE, Schwartz GG, Elbez Y, Szarek M, Bhatt DL, Bittner VA, Diaz R, Erglis A, Goodman SG, Hagstr?m E, Jukema JW, Liberopoulos E, Loy M, Pordy R, White HD, Simon T, Steg PG. Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES. Can J Cardiol. 2022 10; 38(10):1542-1549.
    View in: PubMed
    Score: 0.006
  64. Murphy WA, Lin N, Damask A, Schwartz GG, Steg PG, Szarek M, Banerjee P, Fazio S, Manvelian G, Pordy R, Shuldiner AR, Paulding C. Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial. Circ Genom Precis Med. 2022 06; 15(3):e003503.
    View in: PubMed
    Score: 0.006
  65. White HD, Schwartz GG, Szarek M, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Goodman SG, Jukema JW, Loy M, Pagidipati N, Pordy R, Ristic AD, Zeiher AM, Wojdyla DM, Steg PG. Alirocumab after acute coronary syndrome in patients with a history of heart failure. Eur Heart J. 2022 04 19; 43(16):1554-1565.
    View in: PubMed
    Score: 0.006
  66. Ostadal P, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Chua T, Diaz R, Goodman SG, Huo Y, Jukema JW, Karpov Y, Pordy R, Scemama M, Szarek M, White HD, Schwartz GG. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2022 05; 10(5):330-340.
    View in: PubMed
    Score: 0.006
  67. Lopes RD, Guimar?es PO, Schwartz GG, Bhatt DL, Bittner VA, Budaj A, Dalby AJ, Diaz R, Goodman SG, Harrington RA, Jukema JW, Kiss RG, Loy M, Pordy R, Poulouin Y, Szarek M, White HD, Steg PG. Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial. Am J Med. 2022 07; 135(7):915-918.
    View in: PubMed
    Score: 0.006
  68. Schwartz GG, Olsson AG. Lipid lowering in acute coronary syndromes: new evidence, new questions. Curr Atheroscler Rep. 2002 Jan; 4(1):1-3.
    View in: PubMed
    Score: 0.005
  69. Olsson AG, Schwartz GG. Early initiation of treatment with statins in acute coronary syndromes. Ann Med. 2002; 34(1):37-41.
    View in: PubMed
    Score: 0.005
  70. Kalantar-Zadeh K, Schwartz GG, Nicholls SJ, Buhr KA, Ginsberg HN, Johansson JO, Kulikowski E, Lebioda K, Toth PP, Wong N, Sweeney M, Ray KK. Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial. Clin J Am Soc Nephrol. 2021 05 08; 16(5):705-716.
    View in: PubMed
    Score: 0.005
  71. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001 Apr 04; 285(13):1711-8.
    View in: PubMed
    Score: 0.005
  72. Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, Leiter LA, Landmesser U, Schwartz GG, Friedman A, Wijngaard PLJ, Garcia Conde L, Kastelein JJP. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol. 2021 Mar 09; 77(9):1182-1193.
    View in: PubMed
    Score: 0.005
  73. Nicholls SJ, Schwartz GG, Buhr KA, Ginsberg HN, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Sweeney M, Ray KK. Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study. Cardiovasc Diabetol. 2021 01 07; 20(1):13.
    View in: PubMed
    Score: 0.005
  74. Cummings J, Schwartz GG, Nicholls SJ, Khan A, Halliday C, Toth PP, Sweeney M, Johansson JO, Wong NCW, Kulikowski E, Kalantar-Zadeh K, Lebioda K, Ginsberg HN, Winblad B, Zetterberg H, Ray KK. Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial. J Alzheimers Dis. 2021; 83(4):1703-1715.
    View in: PubMed
    Score: 0.005
  75. Szarek M, Bittner VA, Aylward P, Baccara-Dinet M, Bhatt DL, Diaz R, Fras Z, Goodman SG, Halvorsen S, Harrington RA, Jukema JW, Moriarty PM, Pordy R, Ray KK, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J. 2020 11 21; 41(44):4245-4255.
    View in: PubMed
    Score: 0.005
  76. Tu??n J, Steg PG, Bhatt DL, Bittner VA, D?az R, Goodman SG, Jukema JW, Kim YU, Li QH, Mueller C, Parkhomenko A, Pordy R, Sritara P, Szarek M, White HD, Zeiher AM, Schwartz GG. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. Eur Heart J. 2020 11 07; 41(42):4114-4123.
    View in: PubMed
    Score: 0.005
  77. Schwartz GG. Exploring new strategies for the management of acute coronary syndromes. Am J Cardiol. 2000 Oct 19; 86(8B):44J-49J; discussion 49J-50J.
    View in: PubMed
    Score: 0.005
  78. Diaz R, Li QH, Bhatt DL, Bittner VA, Baccara-Dinet MT, Goodman SG, Jukema JW, Kimura T, Parkhomenko A, Pordy R, Reiner ?, Roe MT, Szarek M, Tse HF, White HD, Zahger D, Zeiher AM, Schwartz GG, Steg PG. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. Eur J Prev Cardiol. 2021 03 23; 28(1):33-43.
    View in: PubMed
    Score: 0.005
  79. Sinnaeve PR, Schwartz GG, Wojdyla DM, Alings M, Bhatt DL, Bittner VA, Chiang CE, Correa Flores RM, Diaz R, Dorobantu M, Goodman SG, Jukema JW, Kim YU, Pordy R, Roe MT, Sy RG, Szarek M, White HD, Zeiher AM, Steg PG. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. Eur Heart J. 2020 06 21; 41(24):2248-2258.
    View in: PubMed
    Score: 0.005
  80. Bhatt DL, Briggs AH, Reed SD, Annemans L, Szarek M, Bittner VA, Diaz R, Goodman SG, Harrington RA, Higuchi K, Joulain F, Jukema JW, Li QH, Mahaffey KW, Sanchez RJ, Roe MT, Lopes RD, White HD, Zeiher AM, Schwartz GG, Gabriel Steg P. Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2020 05 12; 75(18):2297-2308.
    View in: PubMed
    Score: 0.005
  81. Ray KK, Nicholls SJ, Buhr KA, Ginsberg HN, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Sweeney M, Schwartz GG. Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2020 04 28; 323(16):1565-1573.
    View in: PubMed
    Score: 0.005
  82. Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Harrington RA, Jukema JW, White HD, Zeiher AM, Schwartz GG. Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY?OUTCOMES. J Am Coll Cardiol. 2020 02 04; 75(4):448-451.
    View in: PubMed
    Score: 0.005
  83. Schwartz GG, Reis IM. Is cadmium a cause of human pancreatic cancer? Cancer Epidemiol Biomarkers Prev. 2000 Feb; 9(2):139-45.
    View in: PubMed
    Score: 0.005
  84. Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Moriarty PM, Moryusef A, Pordy R, Roe MT, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute?Coronary Syndrome. J Am Coll Cardiol. 2020 01 21; 75(2):133-144.
    View in: PubMed
    Score: 0.005
  85. Zijlstra LE, Schwartz GG, Steg PG, Jukema JW. Reply: Alirocumab in Polyvascular Atherosclerotic Disease. J Am Coll Cardiol. 2020 01 21; 75(2):241.
    View in: PubMed
    Score: 0.005
  86. Jukema JW, Zijlstra LE, Bhatt DL, Bittner VA, Diaz R, Drexel H, Goodman SG, Kim YU, Pordy R, Reiner ?, Roe MT, Tse HF, Montenegro Valdovinos PC, White HD, Zeiher AM, Szarek M, Schwartz GG, Steg PG. Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. Circulation. 2019 12 17; 140(25):2054-2062.
    View in: PubMed
    Score: 0.005
  87. Damask A, Steg PG, Schwartz GG, Szarek M, Hagstr?m E, Badimon L, Chapman MJ, Boileau C, Tsimikas S, Ginsberg HN, Banerjee P, Manvelian G, Pordy R, Hess S, Overton JD, Lotta LA, Yancopoulos GD, Abecasis GR, Baras A, Paulding C. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial. Circulation. 2020 02 25; 141(8):624-636.
    View in: PubMed
    Score: 0.005
  88. Koomen JV, Heerspink HJL, Schrieks IC, Schwartz GG, Lincoff AM, Nicholls SJ, Svensson A, Wedel H, Weichert A, Grobbee DE, Stevens J. Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. Diabetes Obes Metab. 2020 01; 22(1):30-38.
    View in: PubMed
    Score: 0.005
  89. Haarhaus M, Ray KK, Nicholls SJ, Schwartz GG, Kulikowski E, Johansson JO, Sweeney M, Halliday C, Lebioda K, Wong N, Brandenburg V, Beddhu S, Tonelli M, Zoccali C, Kalantar-Zadeh K. Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. Atherosclerosis. 2019 11; 290:59-65.
    View in: PubMed
    Score: 0.005
  90. Goodman SG, Aylward PE, Szarek M, Chumburidze V, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Hanotin C, Harrington RA, Jukema JW, Kedev S, Letierce A, Moryusef A, Pordy R, Ramos L?pez GA, Roe MT, Viigimaa M, White HD, Zeiher AM, Steg PG, Schwartz GG. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. J Am Coll Cardiol. 2019 09 03; 74(9):1177-1186.
    View in: PubMed
    Score: 0.005
  91. White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lopes RD, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Sritara P, Tricoci P, Zeiher AM, Schwartz GG. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. Eur Heart J. 2019 09 01; 40(33):2801-2809.
    View in: PubMed
    Score: 0.005
  92. Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tu??n J, White HD, Zeiher AM, Schwartz GG, Steg PG. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019 08; 7(8):618-628.
    View in: PubMed
    Score: 0.005
  93. Mani P, Puri R, Schwartz GG, Nissen SE, Shao M, Kastelein JJP, Menon V, Lincoff AM, Nicholls SJ. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial. JAMA Cardiol. 2019 04 01; 4(4):314-320.
    View in: PubMed
    Score: 0.005
  94. Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Karpov Y, Moryusef A, Pordy R, Prieto JC, Roe MT, White HD, Zeiher AM, Schwartz GG, Steg PG. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary?Syndrome: ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019 09 03; 74(9):1167-1176.
    View in: PubMed
    Score: 0.004
  95. Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Kimura T, Kiss RG, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Tricoci P, Xavier D, Zeiher AM, Steg PG. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019 02 05; 73(4):387-396.
    View in: PubMed
    Score: 0.004
  96. Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, Drechsler C, Wanner C, Mora S, Lesogor A, Tsimikas S. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018 10 13; 392(10155):1311-1320.
    View in: PubMed
    Score: 0.004
  97. Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, Furie KL, Conwit R, Spatz ES, Lovejoy A, Abbott JD, Jacoby DL, Kolansky DM, Ling FS, Pfau SE, Kernan WN. Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. Circulation. 2018 09 18; 138(12):1210-1220.
    View in: PubMed
    Score: 0.004
  98. Nicholls SJ, Andrews J, Kastelein JJP, Merkely B, Nissen SE, Ray KK, Schwartz GG, Worthley SG, Keyserling C, Dasseux JL, Griffith L, Kim SW, Janssan A, Di Giovanni G, Pisaniello AD, Scherer DJ, Psaltis PJ, Butters J. Effect of Serial Infusions of CER-001, a Pre-? High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial. JAMA Cardiol. 2018 09 01; 3(9):815-822.
    View in: PubMed
    Score: 0.004
  99. Texakalidis P, Giannopoulos S, Jonnalagadda AK, Chitale RV, Jabbour P, Armstrong EJ, Schwartz GG, Kokkinidis DG. Preoperative Use of Statins in Carotid Artery Stenting: A Systematic Review and Meta-analysis. J Endovasc Ther. 2018 Oct; 25(5):624-631.
    View in: PubMed
    Score: 0.004
  100. Schwartz GG, Oliver MF, Ezekowitz MD, Ganz P, Waters D, Kane JP, Texter M, Pressler ML, Black D, Chaitman BR, Olsson AG. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol. 1998 Mar 01; 81(5):578-81.
    View in: PubMed
    Score: 0.004
  101. Savonitto S, Morici N, Nozza A, Cosentino F, Perrone Filardi P, Murena E, Morocutti G, Ferri M, Cavallini C, Eijkemans MJ, St?hli BE, Schrieks IC, Toyama T, Lambers Heerspink HJ, Malmberg K, Schwartz GG, Lincoff AM, Ryden L, Tardif JC, Grobbee DE. Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes. Diab Vasc Dis Res. 2018 01; 15(1):14-23.
    View in: PubMed
    Score: 0.004
  102. Povsic TJ, Scott R, Mahaffey KW, Blaustein R, Edelberg JM, Lefkowitz MP, Solomon SD, Fox JC, Healy KE, Khakoo AY, Losordo DW, Malik FI, Monia BP, Montgomery RL, Riesmeyer J, Schwartz GG, Zelenkofske SL, Wu JC, Wasserman SM, Roe MT. Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. Cardiovasc Drugs Ther. 2017 Aug; 31(4):445-458.
    View in: PubMed
    Score: 0.004
  103. Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN. Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692. Diabetes Care. 2017 04; 40(4):e47-e48.
    View in: PubMed
    Score: 0.004
  104. Morici N, Savonitto S, Ponticelli C, Schrieks IC, Nozza A, Cosentino F, St?hli BE, Perrone Filardi P, Schwartz GG, Mellbin L, Lincoff AM, Tardif JC, Grobbee DE. Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute?Coronary Syndrome. Am J Med. 2017 09; 130(9):1068-1075.
    View in: PubMed
    Score: 0.004
  105. Young LH, Viscoli CM, Curtis JP, Inzucchi SE, Schwartz GG, Lovejoy AM, Furie KL, Gorman MJ, Conwit R, Abbott JD, Jacoby DL, Kolansky DM, Pfau SE, Ling FS, Kernan WN. Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus. Circulation. 2017 May 16; 135(20):1882-1893.
    View in: PubMed
    Score: 0.004
  106. London MJ, Schwartz GG, Hur K, Henderson WG. Association of Perioperative Statin Use With Mortality and Morbidity After Major Noncardiac Surgery. JAMA Intern Med. 2017 02 01; 177(2):231-242.
    View in: PubMed
    Score: 0.004
  107. Nelson K, Schwartz G, Hernandez S, Simonetti J, Curtis I, Fihn SD. The Association Between Neighborhood Environment and Mortality: Results from a National Study of Veterans. J Gen Intern Med. 2017 Apr; 32(4):416-422.
    View in: PubMed
    Score: 0.004
  108. Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care. 2016 Oct; 39(10):1684-92.
    View in: PubMed
    Score: 0.004
  109. Tardif JC, Rhainds D, Brodeur M, Feroz Zada Y, Fouodjio R, Provost S, Boul? M, Alem S, Gr?goire JC, L'Allier PL, Ibrahim R, Guertin MC, Mongrain I, Olsson AG, Schwartz GG, Rh?aume E, Dub? MP. Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes. Circ Cardiovasc Genet. 2016 Aug; 9(4):340-8.
    View in: PubMed
    Score: 0.004
  110. Sweeney JP, Schwartz GG. Applying the results of large clinical trials in the management of acute myocardial infarction. West J Med. 1996 Mar; 164(3):238-48.
    View in: PubMed
    Score: 0.004
  111. Nordmann A, Schwartz G, Vale N, Bucher HC, Briel M. Cochrane corner: early statin therapy in acute coronary syndromes--what is the clinical benefit? Heart. 2016 May; 102(9):653-4.
    View in: PubMed
    Score: 0.004
  112. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O'Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med. 2016 Apr 07; 374(14):1321-31.
    View in: PubMed
    Score: 0.004
  113. Erdmann E, Califf R, Gerstein HC, Malmberg K, Ruilope L, Schwartz GG, Wedel H, Volz D, Ditmarsch M, Svensson A, Bengus M. Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes. Am Heart J. 2015 Jul; 170(1):117-22.
    View in: PubMed
    Score: 0.003
  114. Niesor EJ, Schwartz GG, Perez A, Stauffer A, Durrwell A, Bucklar-Suchankova G, Benghozi R, Abt M, Kallend D. Statin-induced decrease in ATP-binding cassette transporter A1 expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein. Cardiovasc Drugs Ther. 2015 Feb; 29(1):7-14.
    View in: PubMed
    Score: 0.003
  115. Tardif JC, Rh?aume E, Lemieux Perreault LP, Gr?goire JC, Feroz Zada Y, Asselin G, Provost S, Barhdadi A, Rhainds D, L'Allier PL, Ibrahim R, Upmanyu R, Niesor EJ, Benghozi R, Suchankova G, Laghrissi-Thode F, Guertin MC, Olsson AG, Mongrain I, Schwartz GG, Dub? MP. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet. 2015 Apr; 8(2):372-82.
    View in: PubMed
    Score: 0.003
  116. Vale N, Nordmann AJ, Schwartz GG, de Lemos J, Colivicchi F, den Hartog F, Ostadal P, Macin SM, Liem AH, Mills EJ, Bhatnagar N, Bucher HC, Briel M. Statins for acute coronary syndrome. Cochrane Database Syst Rev. 2014 Sep 01; (9):CD006870.
    View in: PubMed
    Score: 0.003
  117. Viscoli CM, Brass LM, Carolei A, Conwit R, Ford GA, Furie KL, Gorman M, Guarino PD, Inzucchi SE, Lovejoy AM, Parsons MW, Peduzzi PN, Ringleb PA, Schwartz GG, Spence JD, Tanne D, Young LH, Kernan WN. Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. Am Heart J. 2014 Dec; 168(6):823-9.e6.
    View in: PubMed
    Score: 0.003
  118. Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Ryd?n L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA. 2014 Apr 16; 311(15):1515-25.
    View in: PubMed
    Score: 0.003
  119. Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, Brennan DM, Koenig W, Jukema JW, Nambi V, Wright RS, Menon V, Lincoff AM, Nissen SE. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA. 2014 Jan 15; 311(3):252-62.
    View in: PubMed
    Score: 0.003
  120. London MJ, Schwartz GG, Henderson WG. Mortality after perioperative ?-blocker use in noncardiac surgery-reply. JAMA. 2013 Aug 14; 310(6):646.
    View in: PubMed
    Score: 0.003
  121. Holmes MV, Simon T, Exeter HJ, Folkersen L, Asselbergs FW, Guardiola M, Cooper JA, Palmen J, Hubacek JA, Carruthers KF, Horne BD, Brunisholz KD, Mega JL, van Iperen EPA, Li M, Leusink M, Trompet S, Verschuren JJW, Hovingh GK, Dehghan A, Nelson CP, Kotti S, Danchin N, Scholz M, Haase CL, Rothenbacher D, Swerdlow DI, Kuchenbaecker KB, Staines-Urias E, Goel A, van 't Hooft F, Gertow K, de Faire U, Panayiotou AG, Tremoli E, Baldassarre D, Veglia F, Holdt LM, Beutner F, Gansevoort RT, Navis GJ, Mateo Leach I, Breitling LP, Brenner H, Thiery J, Dallmeier D, Franco-Cereceda A, Boer JMA, Stephens JW, Hofker MH, Tedgui A, Hofman A, Uitterlinden AG, Adamkova V, Pitha J, Onland-Moret NC, Cramer MJ, Nathoe HM, Spiering W, Klungel OH, Kumari M, Whincup PH, Morrow DA, Braund PS, Hall AS, Olsson AG, Doevendans PA, Trip MD, Tobin MD, Hamsten A, Watkins H, Koenig W, Nicolaides AN, Teupser D, Day INM, Carlquist JF, Gaunt TR, Ford I, Sattar N, Tsimikas S, Schwartz GG, Lawlor DA, Morris RW, Sandhu MS, Poledne R, Maitland-van der Zee AH, Khaw KT, Keating BJ, van der Harst P, Price JF, Mehta SR, Yusuf S, Witteman JCM, Franco OH, Jukema JW, de Knijff P, Tybjaerg-Hansen A, Rader DJ, Farrall M, Samani NJ, Kivimaki M, Fox KAA, Humphries SE, Anderson JL, Boekholdt SM, Palmer TM, Eriksson P, Par? G, Hingorani AD, Sabatine MS, Mallat Z, Casas JP, Talmud PJ. Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol. 2013 Nov 19; 62(21):1966-1976.
    View in: PubMed
    Score: 0.003
  122. Lincoff AM, Tardif JC, Neal B, Nicholls SJ, Ryd?n L, Schwartz GG, Malmberg K, Buse JB, Henry RR, Wedel H, Weichert A, Cannata R, Grobbee DE. Evaluation of the dual peroxisome proliferator-activated receptor a/? agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. Am Heart J. 2013 Sep; 166(3):429-34.
    View in: PubMed
    Score: 0.003
  123. London MJ, Hur K, Schwartz GG, Henderson WG. Association of perioperative ?-blockade with mortality and cardiovascular morbidity following major noncardiac surgery. JAMA. 2013 Apr 24; 309(16):1704-13.
    View in: PubMed
    Score: 0.003
  124. Zamani P, Schwartz GG, Olsson AG, Rifai N, Bao W, Libby P, Ganz P, Kinlay S. Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study. J Am Heart Assoc. 2013 Jan 28; 2(1):e003103.
    View in: PubMed
    Score: 0.003
  125. Nicholls SJ, Cavender MA, Kastelein JJ, Schwartz G, Waters DD, Rosenson RS, Bash D, Hislop C. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. Cardiovasc Drugs Ther. 2012 Feb; 26(1):71-5.
    View in: PubMed
    Score: 0.003
  126. Ryu SK, Mallat Z, Benessiano J, Tedgui A, Olsson AG, Bao W, Schwartz GG, Tsimikas S. Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes. Circulation. 2012 Feb 14; 125(6):757-66.
    View in: PubMed
    Score: 0.003
  127. Vale N, Nordmann AJ, Schwartz GG, de Lemos J, Colivicchi F, den Hartog F, Ostadal P, Macin SM, Liem AH, Mills E, Bhatnagar N, Bucher HC, Briel M. Statins for acute coronary syndrome. Cochrane Database Syst Rev. 2011 Jun 15; (6):CD006870.
    View in: PubMed
    Score: 0.003
  128. Briel M, Vale N, Schwartz GG, de Lemos JA, Colivicchi F, den Hartog FR, Ostadal P, Macin SM, Liem A, Mills E, Bhatnagar N, Bucher HC, Nordmann AJ. Updated evidence on early statin therapy for acute coronary syndromes: meta-analysis of 18 randomized trials involving over 14,000 patients. Int J Cardiol. 2012 Jun 28; 158(1):93-100.
    View in: PubMed
    Score: 0.003
  129. Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. J Am Coll Cardiol. 2009 Jun 09; 53(23):2186-96.
    View in: PubMed
    Score: 0.002
  130. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Bao W, Libby P, Ganz P. Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study. Atherosclerosis. 2009 Oct; 206(2):551-5.
    View in: PubMed
    Score: 0.002
  131. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Szarek M, Waters DD, Libby P, Ganz P. Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arterioscler Thromb Vasc Biol. 2008 Jan; 28(1):142-7.
    View in: PubMed
    Score: 0.002
  132. Olsson AG, Schwartz GG, Szarek M, Luo D, Jamieson MJ. Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study). Am J Cardiol. 2007 Mar 01; 99(5):632-5.
    View in: PubMed
    Score: 0.002
  133. Sullivan A, Chmura K, Cool CD, Keith R, Schwartz GG, Chan ED. Pulmonary capillary hemangiomatosis: an immunohistochemical analysis of vascular remodeling. Eur J Med Res. 2006 May 05; 11(5):187-93.
    View in: PubMed
    Score: 0.002
  134. Briel M, Schwartz GG, Thompson PL, de Lemos JA, Blazing MA, van Es GA, Kayik?ioglu M, Arntz HR, den Hartog FR, Veeger NJ, Colivicchi F, Dupuis J, Okazaki S, Wright RS, Bucher HC, Nordmann AJ. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA. 2006 May 03; 295(17):2046-56.
    View in: PubMed
    Score: 0.002
  135. Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J. 2005 May; 26(9):890-6.
    View in: PubMed
    Score: 0.002
  136. Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, Schwartz GG. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation. 2004 Sep 14; 110(11):1406-12.
    View in: PubMed
    Score: 0.002
  137. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, Ganz P, Libby P. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation. 2004 Jul 27; 110(4):386-91.
    View in: PubMed
    Score: 0.002
  138. London MJ, Itani KM, Perrino AC, Guarino PD, Schwartz GG, Cunningham F, Gottlieb SS, Henderson WG. Perioperative beta-blockade: a survey of physician attitudes in the department of Veterans Affairs. J Cardiothorac Vasc Anesth. 2004 Feb; 18(1):14-24.
    View in: PubMed
    Score: 0.002
  139. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003 Sep 30; 108(13):1560-6.
    View in: PubMed
    Score: 0.002
  140. Schaefer S, Gober JR, Schwartz GG, Twieg DB, Weiner MW, Massie B. In vivo phosphorus-31 spectroscopic imaging in patients with global myocardial disease. Am J Cardiol. 1990 May 01; 65(16):1154-61.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)